Compare ZKIN & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZKIN | SILO |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Apparel |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 8.0M |
| IPO Year | 2017 | N/A |
| Metric | ZKIN | SILO |
|---|---|---|
| Price | $2.02 | $0.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.8K | ★ 123.5K |
| Earning Date | 09-29-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $95,309,093.00 | $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.82 | $0.36 |
| 52 Week High | $6.30 | $3.37 |
| Indicator | ZKIN | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 37.17 | 46.25 |
| Support Level | $1.93 | $0.45 |
| Resistance Level | $2.39 | $0.48 |
| Average True Range (ATR) | 0.20 | 0.03 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 8.82 | 80.32 |
ZK International Group Co Ltd is engaged in the manufacture and marketing of metal pipes. The company is specialized in producing double-press thin-walled stainless steel tubes and fittings, carbon steel tubes and fittings, single-press tubes and fittings, and stainless-steel strips. The products are used in restaurants, hotels, hospitals, firefighting, food, beverage, ships, engines, industrial seawater desalination and systems of direct-drinking water, cold /hot water supply, city water supply, and gas of large/middle scale construction projects.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.